Last updated: 2026-09-09 10:30:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
MoonLake Immunotherapeutics (MLTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $14,93, with a market capitalization of $1,28B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,95 to $62,75. This page covers its latest market performance, valuation, price trends and company information.
$1,28B | |
$15,02 | |
$64,98 | |
$4,25 | |
$14,94 | |
249,00 | |
1,28M | |
-- | |
$62,75 | |
$5,95 | |
-- | |
-- |
MoonLake Immunotherapeutics (MLTX) is trading at $14,93 in pre-market trading as of 2026-09-09 10:02:00, down 0,06% ($0,01) from the previous close of $14,94
Pre-market trading shows how investors are pricing MLTX before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, MoonLake Immunotherapeutics (MLTX) moved from $14,99 to $14,93, representing a decline of 0,39% ($0,06).
The stock traded between $14,63 and $15,77 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 1,04 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15,8%
MLTX is currently trading at $14,93, placing it 15,8% of the way from its 52-week low of $5,95 to its 52-week high of $62,75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 130 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MoonLake Immunotherapeutics (MLTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.